AU2019346147B2 - Bicyclic derivatives as GABAA α5 receptor modulators - Google Patents

Bicyclic derivatives as GABAA α5 receptor modulators Download PDF

Info

Publication number
AU2019346147B2
AU2019346147B2 AU2019346147A AU2019346147A AU2019346147B2 AU 2019346147 B2 AU2019346147 B2 AU 2019346147B2 AU 2019346147 A AU2019346147 A AU 2019346147A AU 2019346147 A AU2019346147 A AU 2019346147A AU 2019346147 B2 AU2019346147 B2 AU 2019346147B2
Authority
AU
Australia
Prior art keywords
methyl
fluorophenyl
methoxy
tetrahydro
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019346147A
Other languages
English (en)
Other versions
AU2019346147A1 (en
Inventor
Péter ERDÉLYI
Gábor László KAPUS
Benedek Imre KÁROLYI
György SZABÓ
György István TÚRÓS
Olivér ÉLIÁS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AU2019346147A1 publication Critical patent/AU2019346147A1/en
Application granted granted Critical
Publication of AU2019346147B2 publication Critical patent/AU2019346147B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019346147A 2018-09-28 2019-09-27 Bicyclic derivatives as GABAA α5 receptor modulators Active AU2019346147B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1800333 2018-09-28
HU1800333A HU231223B1 (hu) 2018-09-28 2018-09-28 GABAA A5 receptor modulátor hatású biciklusos vegyületek
PCT/IB2019/058208 WO2020065597A1 (en) 2018-09-28 2019-09-27 Bicyclic derivatives as gabaa α5 receptor modulators

Publications (2)

Publication Number Publication Date
AU2019346147A1 AU2019346147A1 (en) 2021-05-20
AU2019346147B2 true AU2019346147B2 (en) 2025-01-09

Family

ID=89992765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019346147A Active AU2019346147B2 (en) 2018-09-28 2019-09-27 Bicyclic derivatives as GABAA α5 receptor modulators

Country Status (15)

Country Link
US (1) US12370182B2 (cg-RX-API-DMAC7.html)
EP (1) EP3856342B1 (cg-RX-API-DMAC7.html)
JP (1) JP7480128B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086631A (cg-RX-API-DMAC7.html)
CN (1) CN112805063B (cg-RX-API-DMAC7.html)
AR (1) AR116549A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019346147B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005837A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113072A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190857A1 (cg-RX-API-DMAC7.html)
HU (1) HU231223B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021003670A (cg-RX-API-DMAC7.html)
TW (1) TWI868079B (cg-RX-API-DMAC7.html)
UA (1) UA130217C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020065597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
HU231691B1 (hu) * 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116854685A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-稠环类衍生物、药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071464A1 (en) * 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
JP4148672B2 (ja) 2000-11-17 2008-09-10 武田薬品工業株式会社 イソオキサゾール誘導体
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
BRPI0812521A2 (pt) 2007-06-13 2015-06-23 Glaxosmithkline Llc Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
BRPI1014454A2 (pt) 2009-05-05 2016-04-05 Hoffmann La Roche derivados de isoxazol-pirazol
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB201016088D0 (en) 2010-09-24 2010-11-10 Phase Focus Ltd Improvements in imaging
CN103189062B (zh) 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
RU2582337C2 (ru) 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк
SG10202010119TA (en) 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
MX350717B (es) 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
MX357504B (es) 2012-06-26 2018-07-12 Saniona Aps Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
MA48594B1 (fr) 2016-12-08 2022-05-31 Hoffmann La Roche Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071464A1 (en) * 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives

Also Published As

Publication number Publication date
TWI868079B (zh) 2025-01-01
JP2022502366A (ja) 2022-01-11
CN112805063B (zh) 2024-02-23
EP3856342B1 (en) 2025-12-10
MX2021003670A (es) 2021-08-19
CN112805063A (zh) 2021-05-14
HU231223B1 (hu) 2022-01-28
CA3113072A1 (en) 2020-04-02
US20210386718A1 (en) 2021-12-16
AU2019346147A1 (en) 2021-05-20
BR112021005837A2 (pt) 2021-07-27
TW202035403A (zh) 2020-10-01
UA130217C2 (uk) 2025-12-24
AR116549A1 (es) 2021-05-19
KR20210086631A (ko) 2021-07-08
JP7480128B2 (ja) 2024-05-09
HUP1800333A2 (hu) 2020-04-28
EA202190857A1 (ru) 2021-06-23
EP3856342C0 (en) 2025-12-10
WO2020065597A1 (en) 2020-04-02
EP3856342A1 (en) 2021-08-04
US12370182B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
JP2019520398A (ja) Rock阻害剤としてのスピロラクタム
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
JP7805946B2 (ja) GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体
JP2024536039A (ja) GABAA α5受容体モジュレーターとしての二環式アミン誘導体
EA045543B1 (ru) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA049500B1 (ru) ПРОИЗВОДНЫЕ 1,3-ДИГИДРО-2Н-ПИРРОЛО[3,4-с]ПИРИДИНА КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA
CA3195326A1 (en) 2-oxo-dihydroquinoline-3-carboxamide derivatives as gaba type a receptor modulators
TW202607004A (zh) 6,7-二氫-5H-吡咯並〔1,2a〕咪唑類衍生物及其製備方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)